Timothy Rolph is CSO at Akero Therapeutics, Inc. (AKRO). They have made 15 open-market trades across 1 company since 2022, most recently 2025-12-09.
CIK 0001779479
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKRO | 183,142 | $10.0M |
Shares reported on the most recent Form 4, priced at the 2025-11-28 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKRO | SELL · 10b5-1 | 2025-10-07 | 2025-10-09 | $46.05 | $1.1M | -0.5% | +0.1% | N/A |
| AKRO | SELL | 2025-09-11 | 2025-09-12 | $43.02 | $24K | +9.8% | +24.1% | N/A |
| AKRO | SELL · 10b5-1 | 2025-09-08 | 2025-09-10 | $44.17 | $1.1M | +7.9% | +25.2% | N/A |
| AKRO | SELL · 10b5-1 | 2025-08-05 | 2025-08-07 | $49.30 | $1.2M | -6.2% | -12.1% | +6.5% |
| AKRO | SELL · 10b5-1 | 2025-07-07 | 2025-07-09 | $51.02 | $1.2M | +1.1% | -0.7% | -9.5% |
| AKRO | SELL | 2025-06-18 | 2025-06-20 | $54.84 | $124K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL | 2025-06-10 | 2025-06-12 | $54.00 | $127K | +5.5% | +1.0% | -17.1% |
| AKRO | SELL · 10b5-1 | 2025-06-05 | 2025-06-09 | $54.29 | $2.5M | +0.4% | -5.3% | -17.5% |
| AKRO | SELL · 10b5-1 | 2025-05-06 | 2025-05-08 | $43.61 | $922K | +12.2% | +29.1% | +24.5% |
| AKRO | SELL · 10b5-1 | 2025-04-24 | 2025-04-28 | $41.03 | $513K | +1.2% | +8.2% | +17.5% |
| AKRO | SELL · 10b5-1 | 2025-04-07 | 2025-04-10 | $35.94 | $359K | +14.9% | +20.5% | +48.4% |
| AKRO | SELL | 2025-03-12 | 2025-03-14 | $44.88 | $23K | -1.9% | -14.8% | +21.3% |
| AKRO | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $44.53 | $1.1M | +8.6% | -12.7% | +30.9% |
| AKRO | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $56.52 | $2.1M | -9.4% | -25.3% | -24.0% |
| AKRO | SELL · 10b5-1 | 2025-01-27 | 2025-01-29 | $55.77 | $3.5M | -8.2% | -11.9% | -22.8% |
| AKRO | SELL · 10b5-1 | 2024-12-17 | 2024-12-18 | $31.10 | $118K | -2.7% | -12.1% | +52.3% |
| AKRO | SELL · 10b5-1 | 2024-12-10 | 2024-12-12 | $30.91 | $298K | +0.0% | -20.7% | +60.6% |
| AKRO | SELL | 2024-09-10 | 2024-09-13 | $26.18 | $14K | +2.2% | +9.5% | +5.9% |
| AKRO | SELL | 2024-06-11 | 2024-06-13 | $22.64 | $108K | -5.2% | +13.4% | +5.9% |
| AKRO | SELL | 2024-03-13 | 2024-03-15 | $28.33 | $18K | -9.3% | -19.4% | -8.6% |
| AKRO | SELL | 2023-12-14 | 2023-12-18 | $20.76 | $11K | +5.8% | -1.3% | +21.6% |
| AKRO | SELL · 10b5-1 | 2023-09-13 | 2023-09-25 | $50.34 | $27K | +4.0% | -73.9% | -48.0% |
| AKRO | SELL | 2023-06-16 | 2023-06-21 | $54.79 | $8.6M | -14.8% | -16.4% | -1.8% |
| AKRO | SELL · 10b5-1 | 2023-06-13 | 2023-06-15 | $55.16 | $28K | -19.5% | -20.7% | -10.8% |
| AKRO | SELL | 2022-12-28 | 2022-12-30 | $51.01 | $2.2M | -9.5% | -11.1% | -31.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.